Education
About Us
Working with TipRanks
Follow Us
Ardelyx Inc (DE:41X)
:41X
41X Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.75 - €8.57
Previous CloseN/A
Volume0.00
Average Volume (3M)49.00
Market Cap
€1.10B
Enterprise Value€1.14B
Total Cash (Recent Filing)$34.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
May 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding238,356,220
10 Day Avg. Volume0
30 Day Avg. Volume49
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)31.20
P/FCF Ratio31.20
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.03
Enterprise Value/Ebitda-68.25
Forecast
1Y Price Target
€9.92Price Target Upside136.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial Performance4Q24 was ARDX's first product-driven profitable quarter, and minimal cash impact from operations is expected through FY25.
Market OpportunitiesIbsrela and Xphozah continue to build momentum in large market opportunities with no second-line competition, supporting a clear path to returned profitability.
Bears Say
Investor SentimentA significant overhang on investor sentiment and the stock is expected until there is a resolution to the uncertainty around Medicare patient access for XPHOZAH.
Medicare CoverageXPHOZAH's near-term and long-term outlook remains uncertain since it became unavailable under Medicare Part D.
Stock RatingAnalysts anticipate a substantial drop in XPHOZAH sales due to its inclusion in the Medicare bundle, leading to a downgrade of the stock rating.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.19% Insiders
19.07%
Mutual Funds
11.12% Other Institutional Investors
53.68% Public Companies and
Individual Investors
41X FAQ
What was Ardelyx Inc’s price range in the past 12 months?
Ardelyx Inc lowest stock price was €3.75 and its highest was €8.57 in the past 12 months.
What is Ardelyx Inc’s market cap?
Ardelyx Inc’s market cap is €1.10B.
When is Ardelyx Inc’s upcoming earnings report date?
Ardelyx Inc’s upcoming earnings report date is May 01, 2025 which is in 5 days.
How were Ardelyx Inc’s earnings last quarter?
Ardelyx Inc released its earnings results on Feb 20, 2025. The company reported €0.018 earnings per share for the quarter, beating the consensus estimate of €0.004 by €0.014.
Is Ardelyx Inc overvalued?
According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued.
Does Ardelyx Inc pay dividends?
Ardelyx Inc does not currently pay dividends.
What is Ardelyx Inc’s EPS estimate?
Ardelyx Inc’s EPS estimate is -0.1.
How many shares outstanding does Ardelyx Inc have?
Ardelyx Inc has 238,356,220 shares outstanding.
What happened to Ardelyx Inc’s price movement after its last earnings report?
Ardelyx Inc reported an EPS of €0.018 in its last earnings report, beating expectations of €0.004. Following the earnings report the stock price went down -14.624%.
Which hedge fund is a major shareholder of Ardelyx Inc?
Currently, no hedge funds are holding shares in DE:41X
---
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.92 (136.08% Upside)
€9.92 (136.08% Upside)
Blogger Sentiment
Bullish
DE:41X Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $388.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.64%
12-Months-Change
Fundamentals
Return on Equity
-23.01%
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
---
41X Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Ardelyx demonstrated strong financial growth and successful product launches, particularly with IBSRELA and XPHOZAH, which led to significant revenue increases and a positive financial position. However, challenges such as the loss of Medicare Part D coverage for XPHOZAH and increased operational expenses present potential hurdles. Overall, the positive achievements appear to outweigh the lowlights.Read More>---
41X Stock 12 Month Forecast
Average Price Target
€9.92
▲(136.08% Upside)
Technical Analysis
Celldex
―
MiMedx Group
―
Ocular Therapeutix
―
Aurinia Pharmaceuticals
―
Liquidia Technologies
―
Best Analysts Covering 41X
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+62.52%
reiterated a buy rating 6 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +62.52% per trade.
---